Clarifying the molecular mechanism associated with carfilzomib resistance in human multiple myeloma using microarray gene expression profile and genetic interaction network

被引:12
作者
Zheng, Zhihong [1 ]
Liu, Tingbo [1 ]
Zheng, Jing [1 ]
Hu, Jianda [1 ]
机构
[1] Fujian Med Univ, Dept Hematol, Fujian Prov Key Lab Hematol, Union Hosp, 29 Xinquan Rd, Fuzhou 350001, Fujian, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2017年 / 10卷
基金
中国国家自然科学基金;
关键词
multiple myeloma; carfilzomib; drug resistance; microarray; interaction network; compensate pathways; BREAST-CANCER CELLS; MICRORNA; METABOLISM; AUTOPHAGY;
D O I
10.2147/OTT.S130742
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Carfilzomib is a Food and Drug Administration-approved selective proteasome inhibitor for patients with multiple myeloma (MM). However, recent studies indicate that MM cells still develop resistance to carfilzomib, and the molecular mechanisms associated with carfilzomib resistance have not been studied in detail. In this study, to better understand its potential resistant effect and its underlying mechanisms in MM, microarray gene expression profile associated with carfilzomib-resistant KMS-11 and its parental cell line was downloaded from Gene Expression Omnibus database. Raw fluorescent signals were normalized and differently expressed genes were identified using Significance Analysis of Microarrays method. Genetic interaction network was expanded using String, a biomolecular interaction network JAVA platform. Meanwhile, molecular function, biological process and signaling pathway enrichment analysis were performed based on Gene Ontology and Kyoto Encyclopedia of Genes and Genomes. Totally, 27 upregulated and 36 downregulated genes were identified and a genetic interaction network associated with the resistant effect was expanded basing on String, which consisted of 100 nodes and 249 edges. In addition, signaling pathway enrichment analysis indicated that cytokine-cytokine receptor interaction, autophagy, ErbB signaling pathway, microRNAs in cancer and fatty acid metabolism pathways were aberrant in carfilzomib-resistant KMS-11 cells. Thus, in this study, we demonstrated that carfilzomib potentially conferred drug resistance to KMS-11 cells by cytokine-cytokine receptor interaction, autophagy, ErbB signaling pathway, microRNAs in cancer and fatty acid metabolism pathways, which may provide some potential molecular therapeutic targets for drug combination therapy against carfilzomib resistance.
引用
收藏
页码:1327 / 1334
页数:8
相关论文
共 29 条
  • [1] Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits
    Acosta-Alvear, Diego
    Cho, Min Y.
    Wild, Thomas
    Buchholz, Tonia J.
    Lerner, Alana G.
    Simakova, Olga
    Hahn, Jamie
    Korde, Neha
    Landgren, Ola
    Maric, Irina
    Choudhary, Chunaram
    Walter, Peter
    Weissman, Jonathan S.
    Kampmann, Martin
    [J]. ELIFE, 2015, 4
  • [2] [Anonymous], ANN HEMATOL
  • [3] Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling
    Azad, A. K. M.
    Lawen, Alfons
    Keith, Jonathan M.
    [J]. BMC SYSTEMS BIOLOGY, 2015, 9
  • [4] Identifying antimicrobial resistance genes with DNA microarrays
    Call, DR
    Bakko, MK
    Krug, MJ
    Roberts, MC
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) : 3290 - 3295
  • [5] Cancer metabolism: fatty acid oxidation in the limelight
    Carracedo, Arkaitz
    Cantley, Lewis C.
    Pandolfi, Pier Paolo
    [J]. NATURE REVIEWS CANCER, 2013, 13 (04) : 227 - 232
  • [6] KIAA0101 is associated with human renal cell carcinoma proliferation and migration induced by erythropoietin
    Fan, Shengjun
    Li, Xin
    Tie, Lu
    Pan, Yan
    Li, Xuejun
    [J]. ONCOTARGET, 2016, 7 (12) : 13520 - 13537
  • [7] Layered Signaling Regulatory Networks Analysis of Gene Expression Involved in Malignant Tumorigenesis of Non-Resolving Ulcerative Colitis via Integration of Cross-Study Microarray Profiles
    Fan, Shengjun
    Pan, Zhenyu
    Geng, Qiang
    Li, Xin
    Wang, Yefan
    An, Yu
    Xu, Yan
    Tie, Lu
    Pan, Yan
    Li, Xuejun
    [J]. PLOS ONE, 2013, 8 (06):
  • [8] Clarifying off-target effects for torcetrapib using network pharmacology and reverse docking approach
    Fan, Shengjun
    Geng, Qiang
    Pan, Zhenyu
    Li, Xin
    Tie, Lu
    Pan, Yan
    Li, Xuejun
    [J]. BMC SYSTEMS BIOLOGY, 2012, 6
  • [9] Development of a high-throughput DNA microarray for drug-resistant gene detection and its preliminary application
    Fu, Yali
    Pan, Ying
    Pan, Mingjie
    Wang, Yao
    Liu, Wu
    Li, Yuexi
    [J]. JOURNAL OF MICROBIOLOGICAL METHODS, 2012, 89 (02) : 110 - 118
  • [10] Integrated nonclinical and clinical risk assessment of the investigational proteasome inhibitor ixazomib on the QTc interval in cancer patients
    Gupta, Neeraj
    Huh, Yeamin
    Hutmacher, Matthew M.
    Ottinger, Sean
    Hui, Ai-Min
    Venkatakrishnan, Karthik
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (03) : 507 - 516